| References: |
VX-950 is a potent, selective, peptidomimetic inhibitor of the hepatitis C virus (HCV) NS3-4A serine protease, and it demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells (50% inhibitory concentration [IC50] = 354 nM) and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC50 = 280 nM). VX-950 Forms a covalent but reversible complex with the genotype 1a HCV NS3-4A protease in a slow-on, slow-off process with a steady-state inhibition constant (Ki*) of 7 nM. For the detailed information about the solubility of Telaprevir (VX-950) in water, the solubility of Telaprevir (VX-950) in DMSO, the solubility of Telaprevir (VX-950) in PBS buffer, the animal experiment（test） of Telaprevir (VX-950),the in vivo,in vitro and clinical trial test of Telaprevir (VX-950),the cell experiment（test） of Telaprevir (VX-950),the IC50, EC50 and Affinity of Telaprevir (VX-950), please contact DC Chemicals. |
